Asia Pacific Generic Injectables Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Product Type (Large Molecule Injectables and Small Molecule Injectables), Container Type (Vials, Premix, Prefilled Syringes, Ampoules, and Others), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others), and Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others) 


No. of Pages: 167    |    Report Code: BMIRE00024995    |    Category: Life Sciences

Asia Pacific Generic Injectables Market
Buy Now

The generic injectables market in Asia Pacific is expected to grow from US$ 26,606.06 million in 2021 to US$ 55,751.62 million by 2028; it is estimated to grow at a CAGR of 11.1% from 2021 to 2028.

The patents of branded injectables in several countries are likely to expire in the upcoming years, offering numerous remunerative opportunities to the generic injectables manufacturers. The shortage of branded medicines in India and the expiry of branded drug patents have prompted generic injectable manufacturers to introduce advanced drug delivery systems, including self-injection devices. Biological E Limited, an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio with the addition of 20 routine and injectable products. Thus, generic injectables companies are tapping regulated markets and exploring other markets to generate incomes and establish stable revenue streams. Additionally, manufacturers in the generic injectables market are becoming future-ready by maintaining adequate supply chains to prevent vulnerabilities, such as those caused by the COVID-19 outbreak. Zydus Cadila is significantly reducing the price of its generic version of Remdesivir, namely Remdac. Thus, the nearing expiry of patent validity of branded drugs is likely to provide significant opportunities to generic drug manufacturers, including the companies offering generic injectables.

Asia Pacific Generic Injectables Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Generic Injectables Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report

Asia Pacific Generic Injectables Strategic Insights

Strategic insights for the Asia Pacific Generic Injectables provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-generic-injectables-market-strategic-framework.webp
Get more information on this report

Asia Pacific Generic Injectables Report Scope

Report Attribute Details
Market size in 2021 US$ 26,606.06 Million
Market Size by 2028 US$ 55,751.62 Million
Global CAGR (2021 - 2028) 11.1%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By Product Type
  • Large Molecule Injectables
  • Small Molecule Injectables
By Container Type
  • Vials
  • Premix
  • Prefilled Syringes
  • Ampoules
By Application
  • Oncology
  • Infectious Diseases
  • Cardiology
  • Diabetes
  • Immunology
By Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • AstraZeneca
  • Baxter International Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • Lupin
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Viatris Inc
  • Get more information on this report

    Asia Pacific Generic Injectables Regional Insights

    The geographic scope of the Asia Pacific Generic Injectables refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-generic-injectables-market-geography.webp
    Get more information on this report

    Asia Pacific Generic Injectables Market Segmentation   

    The Asia Pacific generic injectables market is segmented into product type, container type, application, route of administration, and country. Based on product type, the market has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held a larger market share. In terms of container type, the market has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share of the Asia Pacific generic injectables market. Based on application, the market has been segmented into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share of the market. Based on route of administration, the market has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest market share. Based on country, the Asia Pacific generic injectables market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China contributed a substantial share in 2020. 

    AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.;

    Pfizer Inc.

    ;

    and Viatris Inc are among the leading companies in the Asia-Pacific generic injectables market.

    The List of Companies - Asia Pacific Generic Injectables Market

    1. AstraZeneca
    2. Baxter International Inc.
    3. Biocon
    4. Fresenius SE & Co. KGaA
    5. GlaxoSmithKline plc
    6. Johnson and Johnson Services, Inc.
    7. Lupin
    8. Merck & Co., Inc.
    9. Pfizer Inc.
    10. Viatris Inc
    Frequently Asked Questions
    How big is the Asia Pacific Generic Injectables Market?

    The Asia Pacific Generic Injectables Market is valued at US$ 26,606.06 Million in 2021, it is projected to reach US$ 55,751.62 Million by 2028.

    What is the CAGR for Asia Pacific Generic Injectables Market by (2021 - 2028)?

    As per our report Asia Pacific Generic Injectables Market, the market size is valued at US$ 26,606.06 Million in 2021, projecting it to reach US$ 55,751.62 Million by 2028. This translates to a CAGR of approximately 11.1% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Generic Injectables Market report typically cover these key segments-

    • Product Type (Large Molecule Injectables, Small Molecule Injectables)
    • Container Type (Vials, Premix, Prefilled Syringes, Ampoules)
    • Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology)
    • Route of Administration (Intravenous, Intramuscular, Subcutaneous)

    What is the historic period, base year, and forecast period taken for Asia Pacific Generic Injectables Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Generic Injectables Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Asia Pacific Generic Injectables Market?

    The Asia Pacific Generic Injectables Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AstraZeneca
  • Baxter International Inc.
  • Biocon
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline plc
  • Johnson and Johnson Services, Inc.
  • Lupin
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Viatris Inc
  • Who should buy this report?

    The Asia Pacific Generic Injectables Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Generic Injectables Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now